Vanguard Group
ZYME icon

Vanguard Group’s Zymeworks ZYME Stock Holding History

Vanguard Group’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$61.3M Buy
2,328,727
+174,293
+8% +$3.8M ﹤0.01% 2064
2025
Q3 		$36.8M Sell
2,154,434
-310,259
-13% -$4.44M ﹤0.01% 2303
2025
Q2 		$30.9M Buy
2,464,693
+697,652
+39% +$8.31M ﹤0.01% 2349
2025
Q1 		$21M Sell
1,767,041
-726,247
-29% -$9.9M ﹤0.01% 2484
2024
Q4 		$36.5M Sell
2,493,288
-365,226
-13% -$5.11M ﹤0.01% 2296
2024
Q3 		$35.9M Buy
2,858,514
+161,142
+6% +$1.75M ﹤0.01% 2320
2024
Q2 		$23M Buy
2,697,372
+239,267
+10% +$2.13M ﹤0.01% 2503
2024
Q1 		$25.9M Buy
2,458,105
+63,393
+3% +$704K ﹤0.01% 2468
2023
Q4 		$24.9M Buy
2,394,712
+10,726
+0.4% +$85.5K ﹤0.01% 2497
2023
Q3 		$15.1M Buy
2,383,986
+131,604
+6% +$972K ﹤0.01% 2669
2023
Q2 		$19.5M Buy
2,252,382
+212,233
+10% +$1.9M ﹤0.01% 2599
2023
Q1 		$18.4M Sell
2,040,149
-496,246
-20% -$4.33M ﹤0.01% 2618
2022
Q4 		$19.9M Buy
2,536,395
+2,012,412
+384% +$14.1M ﹤0.01% 2630
2022
Q3 		$3.22M Sell
523,983
-82,707
-14% -$499K ﹤0.01% 3546
2022
Q2 		$3.21M Buy
606,690
+193,412
+47% +$1.17M ﹤0.01% 3594
2022
Q1 		$2.71M Buy
413,278
+179,461
+77% +$1.6M ﹤0.01% 3825
2021
Q4 		$3.83M Buy
233,817
+62,261
+36% +$1.3M ﹤0.01% 3760
2021
Q3 		$4.98M Buy
171,556
+6,342
+4% +$211K ﹤0.01% 3665
2021
Q2 		$5.73M Buy
165,214
+34,969
+27% +$1.11M ﹤0.01% 3525
2021
Q1 		$4.11M Buy
130,245
+5,115
+4% +$208K ﹤0.01% 3627
2020
Q4 		$5.91M Buy
125,130
+8,091
+7% +$376K ﹤0.01% 3284
2020
Q3 		$5.45M Buy
117,039
+181
+0.2% +$6.21K ﹤0.01% 3103
2020
Q2 		$4.21M Buy
+116,858
New +$4.3M ﹤0.01% 3179

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group's ZYME Position: Q4 2025 in Review

Vanguard Group increased its Zymeworks (ZYME) stake by 8.1% in Q4 2025, buying an estimated $3.8M and bringing the position to 2,328,727 shares worth $61.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

Vanguard Group first reported a position in ZYME in Q2 2020 and has held it in 23 quarters since. 209 funds tracked by Wall St. Rank hold ZYME as of Q4 2025.

  • Vanguard Group held 2,328,727 shares of Zymeworks worth $61.3M as of Q4 2025.
  • Vanguard Group bought 174,293 Zymeworks shares in Q4 2025, an estimated $3.8M.
  • Zymeworks made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2064 holding.
  • Vanguard Group first reported a position in Zymeworks in Q2 2020 and has held it in 23 quarters since.
  • 209 funds tracked by Wall St. Rank held Zymeworks as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.